Welcome to our Antibody-Directed Enzyme Prodrug Therapy (ADEPT) enzyme selection and optimization service platform! At Creative Biolabs, we are dedicated to assisting you in selecting and optimizing the most effective enzymes during the development of antibody-directed therapies. Our service is designed to enhance the precision and efficacy of treatments, providing more targeted options for cancer care. Our team possesses a deep understanding of ADEPT technology and is prepared to create customized, efficient enzyme screening and optimization strategies tailored to your needs.

Introduction

Antibody-directed prodrugs have been considered an innovative targeted therapy strategy that facilitates precise drug release by linking specific prodrugs with antibodies. The essence of this approach lies in the ability of the prodrugs to be activated within particular cellular environments, thereby minimizing impacts on healthy cells and enhancing the safety and efficacy of treatment.

In our labs, our ADEPT enzyme design and selection service encompasses all stages from enzyme identification to optimization. We begin by gathering biological information related to the target enzyme, including known enzyme structures and functions, genomic and proteomic data, as well as relevant experimental results on activity and selectivity. Next, we employ bioinformatics tools to filter potential enzyme candidates. Using high-throughput screening techniques, such as library screening and enzyme activity assays, we further validate the functionality of these candidates to identify those with catalytic potential. Subsequently, we utilize computational simulation techniques, including molecular docking and dynamics simulations, to conduct structural analyses of the selected candidates, exploring their catalytic mechanisms and substrate binding characteristics in depth. Based on the structural and functional analysis results obtained, we implement strategies such as directed evolution, rational design, or a combination of both, to optimize the enzyme, enhancing its activity, stability, and selectivity.

Fig.1 Antibody-directed Enzyme Prodrug Therapy (ADEPT).^1,3

Services

Recently, ADEPT has become a targeted therapy approach that merges the specificity of monoclonal antibodies with the efficacy of enzyme prodrugs. This strategy enhances drug accumulation at tumor sites while minimizing systemic toxicity. Creative Biolabs offers a variety of professional preclinical Contract Research Organization (CRO) services to support the development of ADEPT.

• Target Selection: It's essential to identify the tumor-specific antigens that the antibodies will target. This requires a thorough understanding of the expression characteristics of tumor cells to ensure effective activation of the prodrug within the tumor microenvironment.
• Enzyme Properties: The enzyme chosen must exhibit high specificity and activity to effectively convert the prodrug. Additionally, its biocompatibility and stability need to be considered to prevent unintended harm to normal cells.
• Physicochemical Properties of the Drug: The prodrug should possess good solubility, bioavailability, and stability to ensure effective delivery and conversion within the body.
• Therapeutic Window: An ideal prodrug should specifically release the active drug within the tumor microenvironment, maximizing local concentration while minimizing systemic toxicity. Hence, it's vital to develop prodrugs that are sensitive to tumor characteristics.
• Preclinical Research: Before selecting a prodrug, comprehensive preclinical studies must be conducted to assess its safety and effectiveness, including both in vitro and in vivo experiments to understand the drug's behavior in biological systems.
• Mechanism Exploration: A deep understanding of the interaction mechanisms between the prodrug and the enzyme is critical for optimizing therapeutic strategies and enhancing tumor selectivity.

Fig.2 Inhibition of the Interaction Between Biotinylated CM79 Antibody by MFECPHis and A5CP.^2,3

Features

Exploring the future of antibody-guided prodrug therapies, Creative Biolabs provides a wide collection of ADEPT enzyme selection and optimization services. Our team boasts extensive experience and in-depth expertise, enabling us to create tailored enzyme solutions that enhance both the efficacy and safety of your pharmaceuticals.

• Precision Targeting: Creative Biolabs uses highly specific antibodies combined with enzymes to ensure that the drug accurately targets tumor cells, thereby minimizing damage to normal cells and enhancing therapeutic efficacy.
• Efficient Screening System: By employing advanced screening technologies and high-throughput experimental platforms, our staff can swiftly identify the most suitable enzyme candidates.
• Comprehensive Multi-Disciplinary Services: Our scientists leverage the latest research findings and technological advancements to ensure our services remain at the forefront of the industry.
• Rigorous Quality Control: We implement stringent quality control standards at every stage of the experiment to guarantee the reliability and reproducibility of our results.
• Thorough Follow-Up Services: In addition to initial enzyme selection and optimization, Creative Biolabs also offers subsequent data analysis and interpretation services, providing support for our clients' further research to make it more in-depth and productive.

Selecting the right enzyme is crucial for success in ADEPT. Creative Biolabs brings extensive experience and advanced technology to help you screen and optimize enzymes tailored to your specific needs, ensuring outstanding results in your clinical research. Whether you are in the early stages of development or already in the clinical phase, we are here to provide you with comprehensive support and guidance. If you're interested in our enzyme selection and optimization services for ADEPT, please feel free to contact us at any time.

References

1. El-Sayed, Ashraf SA, et al. "Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene-directed enzyme prodrug therapy." Heliyon 8.9 (2022).
2. Mayer, A., et al. "Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)." British journal of cancer 90.12 (2004): 2402-2410.
3. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use